Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 30 Oct 2026
Underserved or high-risk populations

Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors.

Among cancer survivors with diabetes, semaglutide showed lower cardiovascular risk than other GLP-1 drugs over five years.

This target-trial emulation using an electronic-health-record cohort examined semaglutide versus other glp-1 ras and cardiovascular risk in obesity-related cancer survivors. The PubMed abstract reports among 918 matched obesity-related cancer survivors with diabetes, semaglutide was associated with a lower five-year major cardiovascular event risk than other glp-1 receptor agonists.

What the study was

Study design
Target-trial emulation using an electronic-health-record cohort
Population
Obesity-related cancer survivors with type 2 diabetes
Sample size
459
Category
Treatment Innovation
Maturity
Validated
Journal
Diabetes research and clinical practice

Why it surfaced

Score reflects the target-trial emulation using an electronic-health-record cohort design and relevance to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; classification is limited to PubMed title, metadata, and abstract evidence.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.